secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110821
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q3 revenue flat at $17.9M; net income down to $2.4M; PRX-115 phase 2 IND effective
--------------------------------------------------------------------------------

- Q3 2025 revenue flat at $17.9M; net income $2.4M ($0.03 EPS) vs $3.2M ($0.04) in Q3 2024.
- Nine-month 2025 revenue $43.6M (+24% YoY); net loss improved to $1.1M from $3.6M.
- PRX-115 IND effective; phase 2 trial for uncontrolled gout planned for late 2025.
- Chiesi requested re-examination of CHMP negative opinion on Elfabrio 2 mg/kg E4W; 1 mg/kg E2W still approved.
- Cash and equivalents $29.4M at Sep 30, 2025; sufficient for at least 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/0001104659-25-110821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/plx-20251113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer